General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MIBTH
ADC Name
5E3-Saporin ADC
Synonyms
5E3-Fab-SAP
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
Antibody Name
Anti-SEMA4A mAb 5E3
 Antibody Info 
Antigen Name
Semaphorin-4A (SEMA4A)
 Antigen Info 
Payload Name
Saporin
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
5.9
pM
NCI-H929 cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
10.6
pM
MM1.S cells
Plasma cell myeloma
Half Maximal Inhibitory Concentration (IC50) 
> 100
nM
K562 cells
Chronic myeloid leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 5.90 pM Positive SEMA4A expression (SEMA4A +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 10.60 pM Positive SEMA4A expression (SEMA4A +++/++)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 100 nM Negative SEMA4A expression (SEMA4A -)
Method Description
Cells were seeded at 5000 per well in a 96-well plate in complete RPMI 1640. Antibody-ZAP complexes (Advanced Targeting Systems; produced according to manufacturer's instructions) or ADCs were added to the cells and plates incubated for 72 hours and 5% carbon dioxide.
In Vitro Model Chronic myeloid leukemia K562 cells CVCL_0004
References
Ref 1 Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022 Apr 21;139(16):2471-2482. doi: 10.1182/blood.2021015161.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.